Fw: SPECIAL ANNOUNCEMENT: CDSA 2.0 LAUNCH

[Guest guest]

From another list - thought this might be useful.

Donna in NC

>

> **************SPECIAL ANNOUNCEMENT**************

>

> -GREAT SMOKIES DIAGNOSTIC LABORATORY ANNOUNCES LAUNCH OF

> COMPREHENSIVE DIGESTIVE STOOL ANALYSIS 2.0

>

> - RECENT SCIENTIFIC ADVANCES YIELD NEW GOLD STANDARD FOR NONINVASIVE

> ANALYSIS OF GASTROINTESTINAL FUNCTION

>

> As health care practitioners well know, digestive complaints are

> among the most common reasons that individuals seek medical care.

>

> According to the National Digestive Disease Information Clearing

> House, there are 22 million reported cases of acute digestive

> conditions, including indigestion, abdominal pain, and bowel

> dysfunction, in the U.S. each year. Digestive diseases kill nearly

> 200,000 Americans annually, and account for health care expenditures

> totaling over $100 billion.

>

> In addition, the relationship between digestive symptoms and systemic

> diseases, such as rheumatoid arthritis, multiple sclerosis, and

> chronic fatigue, is receiving greater attention in current medical

> research.

>

> For these reasons, there is enormous clinical need for a more

> advanced noninvasive diagnostic tool to improve prevention and target

> treatment strategies for gastrointestinal disorders.

>

> Great Smokies Diagnostic Laboratory (GSDL) announces the launch of

> the latest version of its leading diagnostic assessment, the

> Comprehensive Digestive Stool Analysis (CDSA). The enhanced

> assessment, developed by gaining exclusive rights to recent

> proprietary advances in gastroenterology and biotechnology research,

> offers physicians unparalleled insight into the diagnosis and

> treatment of patients with digestive conditions, such as irritable

> bowel syndrome and inflammatory bowel disease. This novel diagnostic

> panel also explores the risk factors for serious gastrointestinal

> diseases such as colorectal cancer.

>

> NEW TEST EXPANDS DIAGNOSTIC SCOPE, IMPROVES CLINICAL PRECISION

>

> In addition to providing a comprehensive evaluation of gut microbial

> ecology and digestive function, the new CDSA 2.0 offers expanded

> diagnostic capability for physicians to:

>

> - Distinguish definitively between chronic functional digestive

> disorders like Irritable Bowel Syndrome and organic diseases such as

> Inflammatory Bowel Disease.

>

> - Utilize the most sensitive markers for noninvasive risk assessment

> of colorectal cancer, the second leading cause of cancer death in the

> U.S.

>

> - Evaluate pancreatic digestive enzyme output without interference

> from digestive supplements, changes in stool transit time, or marker

> variability.

>

> - Improve speed and accuracy in monitoring eradication therapy for H.

> pylori, the causal bacterium in peptic ulcer disease.

>

> The 2.0 version also significantly expands a clinician's ability to

> identify pathogenic yeast and parasites in the gastrointestinal tract

> through a proprietary Optimized Parasite Recovery technology. In

> addition, the analysis detects both C. difficile toxins A and B, the

> number one cause of antibiotic-associated diarrhea.

>

> " The innovations of the new CDSA 2.0 have made it the gold standard

> of comprehensive digestive analysis, " observes Leonard , M.D.,

> General and Gastrointestinal Surgeon and Courtesy Assistant Professor

> in the Department of Medicine at the University of Florida College of

> Medicine in Gainesville. The test allows physicians to diagnose,

> assess, and monitor a wider range of gastrointestinal conditions-with

> greater clinical precision-than ever before.

>

> Recognizing the central role of the digestive tract in health and

> disease, GSDL introduced the original CDSA in 1987. The assessment

> quickly set the industry standard for noninvasive digestive analysis.

> Over the last two decades, it has become an essential diagnostic tool

> for thousands of physicians worldwide.

>

> The CDSA 2.0 builds upon the successful foundation of the original

> assessment by adding cutting-edge markers such as calprotectin, a

> sensitive indicator of inflammation in the bowel.

>

> " Significantly increased levels of calprotectin may be a strong

> indication of neoplastic [tumor-forming] processes in the

> gastrointestinal tract-even in the presence of negative results from

> other diagnostic evaluations, such as colonoscopy, " observes Magne K.

> Fagerhol, Ph.D., of the Department of Immunology and Transfusion

> Medicine at Ullevaal University in Oslo, Norway. " This enhanced

> detection ability could save patient lives. "

>

> Another novel marker, pancreatic elastase 1, provides an extremely

> reliable indicator of exocrine pancreatic function-critical in the

> evaluation of patients with unexplained maldigestion or abdominal

> pain. Pancreatic exocrine dysfunction has been observed in up to 30%

> of type I and type II diabetics.

>

> " Currently pancreatic elastase 1 appears to be the best noninvasive

> assessment of pancreatic function available, " says P Toskes,

> M.D., Professor of Medicine in the Division of Gastroenterology,

> Hepatology, and Nutrition at the University of Florida College of

> Medicine in Gainesville. " Its sensitivity and specificity outperform

> other noninvasive pancreatic tests that have been evaluated. "

>

> The CDSA 2.0 will help physicians develop earlier, more effective

> preventive interventions, improve the timing and precision of

> treatments, and reduce the risk of clinical relapse in certain groups

> of patients. It will also allow physicians to better evaluate and

> document the medical necessity for more invasive procedures, such as

> colonoscopy.

>

> TO RECEIVE MORE INFORMATION.

>

> Learn more about the advanced diagnostic capability of the CDSA 2.0

> and how it can better guide your clinical interventions to improve

> digestive function and overall health.

>

> Visit our Digestive Analysis Solution Center at http://www.gsdl.com/

> for more in-depth information on the CDSA 2.0. From the site,

> practitioners can order kits, receive results online, access the CDSA

> 2.0 Support Guide, and register for educational web casts.

>

> Or call 1-800-522-4762 to order CDAS 2.0 kits with improved

> collection devices.